Seventh Sense Biosystems Inc. Receives Notice Of Allowance For Additional U.S. Patents For TAP Blood Collection System

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems, Inc., (7SBio), a leading developer of blood collection and diagnostic platforms, announced today the receipt of notice of allowances from the United States Patent and Trademark Office for two patent applications (U.S. Patent Applications 13/016,575 and 13/166,451) in addition to the four patents the company has already received.

“The ongoing validation of our novel and innovative platform through the U.S. patent system continues to be a source of momentum for Seventh Sense and we anticipate more issuances in the near future as we progress towards the commercialization of the TAP platform of blood collection and diagnostic tools”

The allowed patent claims cover specific design features associated with 1) delivering less pain than a ‘finger stick’ and 2) reporting and interfacing with external information systems using the TAP device in conjunction with patient compliance and prescription therapeutic monitoring. Coupled with previously issued patents which cover collection of any volume of blood and the use of microneedles, microfluidics and a vacuum to cause blood flow, these patent allowances will confer additional protection for 7SBio’s proprietary Touch Activated Phlebotomy (TAP) technology platform.

“The ongoing validation of our novel and innovative platform through the U.S. patent system continues to be a source of momentum for Seventh Sense and we anticipate more issuances in the near future as we progress towards the commercialization of the TAP platform of blood collection and diagnostic tools,” said Howard Weisman, CEO at 7SBio. “Non-compliance of patients who are fearful of pain or large needles associated with blood tests is an important, unaddressed problem which our products solve in a meaningful way. With the crossing of each new positive milestone, an essentially pain-free, easy-to-use and mobile solution is closer to reality.”

With the anticipated issuance of these two patents, the company will have a total of six US patents, with numerous other patents pending worldwide.

“Unlike companies that are developing proprietary systems that miniaturize the process of blood collection and analysis for clinicians only, 7SBio is developing an open, ubiquitous platform that can interface with many systems and be used by patients and health care providers alike,” said Weisman. “We share a responsibility for delivering the highest quality of healthcare wherever it’s needed and we’re working with the US Patent and Trademark Office and the FDA to ensure the efficacy, safety and intellectual property rights of the TAP platform in all its forms and uses.”

About the TAP Touch Activated Phlebotomy ^® and TAP Blood Collection Device^®
TAP is a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein, and it can be utilized across and integrated with a broad spectrum of diagnostic applications. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.

About Seventh Sense Biosystems, Inc.
Founded in 2008, Seventh Sense Biosystems is developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. The company’s initial focus is on improving important diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection. 7SBio receives funding from investors Flagship Venture Partners, Lighthouse Capital Partners, and Polaris Partners. For more information, please visit www.7sbio.com.